Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2003-5-22
pubmed:abstractText
A total of 6,991 unique patient isolates of Streptococcus pneumoniae were collected from October 1997 to June 2002 from 25 medical centers in 9 of the 10 Canadian provinces. Among these isolates, 20.2% were penicillin nonsusceptible, with 14.6% being penicillin intermediate (MIC, 0.12 to 1 microg/ml) and 5.6% being penicillin resistant (MIC, > or =2 microg/ml). The proportion of high-level penicillin-resistant S. pneumoniae isolates increased from 2.4 to 13.8% over the last 3 years of the study, and the proportion of multidrug-resistant S. pneumoniae isolates increased from 2.7 to 8.8% over the 5-year period. Resistant rates (intermediate and resistant) among non-beta-lactam agents were as follows: macrolides, 9.6 to 9.9%; clindamycin, 3.8%; doxycycline, 5.5%; chloramphenicol, 3.9%; and trimethoprim-sulfamethoxazole, 19.0%. Rates of resistance to non-beta-lactam agents were higher among penicillin-resistant strains than among penicillin-susceptible strains. No resistance to vancomycin or linezolid was observed; however, 0.1% intermediate resistance to quinupristin-dalfopristin was observed. The rate of macrolide resistance (intermediate and resistant) increased from 7.9 to 11.1% over the 5 years. For the fluoroquinolones, the order of activity based on the MICs at which 50% of isolates are inhibited (MIC(50)s) and the MIC(90)s was gemifloxacin > clinafloxacin > trovafloxacin > moxifloxacin > grepafloxacin > gatifloxacin > levofloxacin > ciprofloxacin. The investigational compounds ABT-773 (MIC(90), 0.008 microg/ml), ABT-492 (MIC(90), 0.015 microg/ml), GAR-936 (tigecycline; MIC(90), 0.06 microg/ml), and BMS284756 (garenoxacin; MIC(90), 0.06 micro g/ml) displayed excellent activities. Despite decreases in the rates of antibiotic consumption in Canada over the 5-year period, the rates of both high-level penicillin-resistant and multidrug-resistant S. pneumoniae isolates are increasing in Canada.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-10223606, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-10223962, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-10413735, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-10449461, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-10508032, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-10639387, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-11023465, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-11324679, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-11353617, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-11408241, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-11597287, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-11751784, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-11790155, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-1576274, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-1731029, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-2813426, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-29219, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-7425601, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-7574521, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-7623879, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-7729674, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-8604171, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-8878605, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-8891138, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-8896499, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-9484256, http://linkedlifedata.com/resource/pubmed/commentcorrection/12760860-9564457
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
47
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1867-74
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:12760860-Adolescent, pubmed-meshheading:12760860-Adult, pubmed-meshheading:12760860-Aged, pubmed-meshheading:12760860-Anti-Bacterial Agents, pubmed-meshheading:12760860-Canada, pubmed-meshheading:12760860-Drug Resistance, Multiple, Bacterial, pubmed-meshheading:12760860-Erythromycin, pubmed-meshheading:12760860-Female, pubmed-meshheading:12760860-Fluoroquinolones, pubmed-meshheading:12760860-Humans, pubmed-meshheading:12760860-Indoles, pubmed-meshheading:12760860-Ketolides, pubmed-meshheading:12760860-Longitudinal Studies, pubmed-meshheading:12760860-Male, pubmed-meshheading:12760860-Microbial Sensitivity Tests, pubmed-meshheading:12760860-Middle Aged, pubmed-meshheading:12760860-Minocycline, pubmed-meshheading:12760860-Pneumococcal Infections, pubmed-meshheading:12760860-Quinolones, pubmed-meshheading:12760860-Respiratory Tract Infections, pubmed-meshheading:12760860-Streptococcus pneumoniae, pubmed-meshheading:12760860-beta-Lactam Resistance
pubmed:year
2003
pubmed:articleTitle
Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
pubmed:affiliation
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't